{'fraction_non_alphanumeric': 0.047244094488188976, 'fraction_numerical': 0.03805774278215223, 'mean_word_length': 4.155405405405405, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prevention of Diabetes in Non-Obese Diabetic (NOD) Mice by Short-Term and High-Dose IGF-I Treatment

This report describes the results of IGF-I treatment in a NOD mouse colony with a high incidence of overt diabetes. The animals were treated with IGF-I 17.9 nmol/day at 28-41 days of age and 35.9 nmol/day at 42-69 days of age and observed up to 280 days of age. Three of 12 (25%) IGF-I-treated animals developed diabetes compared with 8 of 11 (73%) controls (P < 0.05). The severity of insulitis at the conclusion of the follow-up was less pronounced in non-diabetic treated animals than in non-diabetic controls. These data support previous findings that IGF-I treatment protects the pancreatic beta-cells from destruction by diabetic autoimmunity in NOD mice.